What Is DPDPE? Definition and What Research Reports

Definition

DPDPE is the standard abbreviation for [D-Pen²,D-Pen⁵]-enkephalin, a synthetic cyclic pentapeptide derived from the endogenous opioid peptide enkephalin and used in laboratory research as a selective agonist at the delta-opioid receptor. The name is an initialism of its own structure: two D-penicillamine residues replace positions 2 and 5 of the enkephalin backbone, and the sulfur atoms of those residues form a disulfide bridge that locks the molecule into a constrained ring. That conformational constraint is what gives DPDPE its characteristic receptor selectivity and its resistance to the rapid enzymatic breakdown that limits native enkephalins. In the published literature it appears almost exclusively as a pharmacological probe — a way for researchers to ask what happens when delta-opioid receptors, rather than mu- or kappa-opioid receptors, are switched on in a tissue, cell line or animal model. DPDPE is not an approved drug in any jurisdiction and is handled as a research-use-only chemical.

What Class of Molecule Is DPDPE?

DPDPE belongs to the opioid peptide class. Its parent molecules, the enkephalins, are five-amino-acid neuropeptides produced naturally in the brain, spinal cord, gut and adrenal tissue, where they act on opioid receptors as part of endogenous pain modulation. Native enkephalins are short-lived; DPDPE was designed as a cyclised analogue to survive longer and to bind the delta-opioid receptor subtype preferentially.

Structurally, DPDPE sits in the same family as other engineered enkephalin analogues. A 2019 synthesis study used on-resin click chemistry to build novel enkephalin analogues and reported potent anti-nociceptive activity for the resulting compounds, with DPDPE-type peptides serving as the structural starting point for that medicinal-chemistry work (PMID 30962495). That paper illustrates the usual role of the term in chemistry literature: a reference scaffold against which newer analogues are compared.

Quick reference

How the Term Is Used in Peptide Research

When a paper says a tissue was “treated with DPDPE,” the shorthand generally means the investigators wanted to isolate delta-opioid receptor signalling. Because the compound is peptidic and relatively selective, it is frequently paired with a delta-selective antagonist such as naltrindole so that any observed effect can be attributed to the receptor rather than to a non-specific action. The term therefore functions in the literature less as the name of a candidate drug and more as the name of an experimental condition.

Research groups have applied that approach across several unrelated fields:

• Cardiac ischaemia and preconditioning — testing whether delta-opioid activation limits injury in the heart.
• Neuroprotection — testing whether delta receptors mediate tolerance induced by low-oxygen preconditioning.
• Analgesia and peptide chemistry — as a benchmark agonist for newer anti-nociceptive analogues.
• Feeding and metabolic behaviour — probing how delta signalling changes intake of different diets.
• Receptor biology — studying desensitisation, internalisation and membrane transport of a peptide agonist.

What the Published Literature Reports

Cardiac ischaemia-reperfusion

The heart has been the most active area. A 2024 in vivo comparison evaluated peptide and non-peptide delta- and kappa-opioid receptor agonists for infarct-limiting activity during myocardial reperfusion and reported that the agonists tested differed in their capacity to reduce infarct size in that reperfusion model (PMID 38340196). Earlier mechanistic work reported that reduction of ischaemia/reperfusion injury involved delta-opioid regulation of intrinsic cardiac adrenergic cells, a pattern the authors described as adrenopeptidergic co-signalling (PMID 19581316). A related paper reported that delta-opioid stimulation augmented cardiac contraction through combined beta-adrenergic and CGRP-receptor signalling rather than through the opioid receptor acting alone (PMID 22108711).

Age appears to modify these effects. In one study, researchers reported that impaired p38 MAPK/HSP27 signalling underlay an aging-related failure of opioid-mediated cardioprotection, meaning the protective response seen in younger tissue was not reproduced in older tissue (PMID 17407780).

Nervous system and analgesia

A 2019 study examined the neuroprotective role of delta-opioid receptors in hypoxic preconditioning and reported that delta-receptor signalling contributed to the protection conferred by that preconditioning stimulus (PMID 31652039). On the analgesia side, the click-chemistry synthesis paper reported potent anti-nociceptive activity for its novel enkephalin analogues in preclinical testing (PMID 30962495).

Feeding, reflexes and other systems

A mouse study reported that delta-opioid receptor activation stimulated intake of a normal diet but conversely suppressed intake of a high-fat diet, a dissociation the authors highlighted as diet-dependent (PMID 24401991). In cardiovascular reflex physiology, researchers reported that peripheral delta-opioid receptors attenuated the exercise pressor reflex (PMID 23934854). In oncology-adjacent work, a combined opiate agonist and antagonist treatment was reported to reduce growth of a prolactin-secreting pituitary tumour model (PMID 28144772).

Receptor Behaviour and Transport: What Studies Report

Two strands of the literature deal with what happens to the peptide and its receptor rather than with downstream outcomes. A 2001 study measured uptake and efflux of the peptidic delta-opioid receptor agonist and reported that transport processes governed its movement across the barrier studied, which is relevant to why peptide agonists and small-molecule agonists can behave differently in the same model (PMID 11257421). Another 2001 paper examined desensitisation of endogenously expressed delta-opioid receptors and reported no evidence that G protein-coupled receptor kinase 2 was involved in that desensitisation (PMID 11728419).

Off-Target and Immune Effects: What Studies Report

Delta-opioid agonism is not confined to neurons and cardiomyocytes. One immunology study reported that opioids triggered alpha-5-beta-1 integrin-mediated monocyte adhesion, indicating that opioid receptor activation can alter immune cell behaviour in vitro (PMID 16424197). The cardiac literature also reported that the apparent protective effect was not uniform: an aging-related failure of opioid-mediated cardioprotection was tied to disrupted p38 MAPK/HSP27 signalling (PMID 17407780). These findings are mechanistic observations from laboratory models, not clinical safety data, and the verified literature summarised here does not include human adverse-event reporting for this compound.

Limits of the Evidence

The body of work involving DPDPE is preclinical. It consists of isolated tissue preparations, cultured cells and rodent models, and it is oriented toward understanding the delta-opioid receptor rather than toward developing DPDPE itself as a treatment. Effects reported in one species, tissue or diet condition have not always translated to another — the opposite directions of feeding response depending on diet type (PMID 24401991) and the loss of cardioprotection with age (PMID 17407780) are both examples of that context dependence. Readers encountering the term in a paper should note which model, which route and which antagonist controls were used before generalising the finding.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or before making decisions related to any substance. PeptideU summarises published research and does not sell or recommend any compound.

References

• Neuroprotective role of delta opioid receptors in hypoxic preconditioning (Turkish Journal of Medical Sciences, 2019)
• On resin click-chemistry-mediated synthesis of novel enkephalin analogues with potent anti-nociceptive activity (Scientific Reports, 2019)
• Impaired p38 MAPK/HSP27 signaling underlies aging-related failure in opioid-mediated cardioprotection (Journal of Molecular and Cellular Cardiology, 2007)
• Delta-opioid augments cardiac contraction through β-adrenergic and CGRP-receptor co-signaling (Peptides, 2012)
• A combined opiate agonist and antagonist treatment reduces prolactin secreting pituitary tumor growth (Journal of Cell Communication and Signaling, 2017)
• δ-Opioid receptor activation stimulates normal diet intake but conversely suppresses high-fat diet intake in mice (American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 2014)
• Peripheral δ-opioid receptors attenuate the exercise pressor reflex (American Journal of Physiology: Heart and Circulatory Physiology, 2013)
• Uptake and efflux of the peptidic delta-opioid receptor agonist (Neuroscience Letters, 2001)
• Comparative Analysis of Infarct-Limiting Activity of Peptide and Non-Peptide δ- and κ-Opioid Receptor Agonists during Heart Reperfusion In Vivo (Bulletin of Experimental Biology and Medicine, 2024)
• Reducing ischaemia/reperfusion injury through delta-opioid-regulated intrinsic cardiac adrenergic cells: adrenopeptidergic co-signalling (Cardiovascular Research, 2009)
• Desensitization of endogenously expressed delta-opioid receptors: no evidence for involvement of G protein-coupled receptor kinase 2 (European Journal of Pharmacology, 2001)
• Opioids trigger alpha 5 beta 1 integrin-mediated monocyte adhesion (Journal of Immunology, 2006)